PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)

被引：0
|
作者：
Saba, N. [1 ]
Youssoufian, H. [2 ]
Cohen, E. [3 ]
Singh, J. [4 ]
Makris, L. [5 ]
Perdomini, M. [6 ]
MacIntyre, S.
Denker, A. [7 ]
机构：
[1] Emory Univ, Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA
[2] Youssoufian Hagop, Med, Boston, MA USA
[3] UC San Diego Hlth, Med Dept, Moores Canc Ctr, La Jolla, CA USA
[4] AMR Kansas City Oncol, Med Dept, Kansas City, MO USA
[5] Stathmi, Stat, New Hope, PA USA
[6] Flamingo Therapeut, Clin Dev, Illkirch Graffenstaden, France
[7] Flamingo Therapeut, Clin Dev, Philadelphia, PA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
943TiP
引用
收藏
页码：S592 / S592
页数：1
相关论文
共 50 条
  • [31] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (vol 394, pg 1915, 2019)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    LANCET, 2020, 395 (10224): : 564 - 564
  • [32] Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
    Hughes, B. G. M.
    Munoz-Couselo, E.
    Mortier, L.
    Bratland, A.
    Gutzmer, R.
    Roshdy, O.
    Mendoza, R. Gonzalez
    Schachter, J.
    Arance, A.
    Grange, F.
    Meyer, N.
    Joshi, A.
    Billan, S.
    Zhang, P.
    Gumuscu, B.
    Swaby, R. F.
    Grob, J. -j.
    ANNALS OF ONCOLOGY, 2021, 32 (10) : 1276 - 1285
  • [33] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (vol 394, pg 1915, 2019)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    LANCET, 2020, 395 (10220): : 272 - 272
  • [34] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, E. E. W.
    Algazi, A.
    Laux, D.
    Wong, D. J.
    Amin, A.
    Nabell, L.
    Chisamore, M.
    Gamelin, E.
    Janssen, R.
    Bishnoi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 375 - 375
  • [35] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, Ezra
    Bishnoi, Sarwan
    Laux, Douglas E.
    Wong, Deborah
    Amin, Asim
    Nabell, Lisle
    Schmidt, Emmett V.
    Xing, Biao
    Leung, Abraham C.
    Janssen, Robert
    CANCER RESEARCH, 2018, 78 (13)
  • [36] STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma
    Saba, Nabil F.
    Harrington, Kevin Joseph
    Licitra, Lisa F.
    Machiels, Jean-Pascal H.
    Huang, Mei
    Xu, Fiona
    Patel, Pritesh
    Haddad, Robert I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis
    Sacco, A. G.
    Chen, R.
    Ghosh, D.
    Worden, F.
    Wong, D. J.
    Adkins, D.
    Swiecicki, P. L.
    Chai-Ho, W.
    Pittman, E.
    Messer, K.
    Gold, K. A.
    Daniels, G.
    Sutton, B.
    Natsuhara, A.
    Cohen, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1121 - 1122
  • [38] Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
    Dillon, Magnus T.
    Grove, Lorna
    Newbold, Kate L.
    Shaw, Heather
    Brown, Nicholas F.
    Mendell, Jeanne
    Chen, Shuquan
    Beckman, Robert A.
    Jennings, Anne
    Ricamara, Marivic
    Greenberg, Jonathan
    Forster, Martin
    Harrington, Kevin J.
    CLINICAL CANCER RESEARCH, 2019, 25 (02) : 487 - 495
  • [39] A phase I study of avelumab, palbociclib, and cetuximab (APC) in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC).
    Gold, Kathryn A.
    Sacco, Assuntina
    Bykowski, Julie
    Daniels, Gregory
    Pittman, Emily
    Messer, Karen
    Chen, Ruifeng
    Cohen, Ezra
    CANCER RESEARCH, 2021, 81 (13)
  • [40] Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Yan, Q.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S855 - S856
12345